Fate Therapeutics
Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.
FT819 is a clonal iPSC-derived CD19 CAR-T; FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy. Presentations at ASCO and EULAR 2026; solid-tumour collaboration with Ono.
Pages like this
not linked directly; found by shared links- CompanySana Biotechnology
Shares Qualify one iPSC master cell bank once for many off-the-shelf cell products, Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyNkarta
Shares Off-the-shelf natural killer cells to sweep up residual disease, CAR-NK & CAR-macrophage, CD19, Diffuse large B-cell lymphoma.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyAllogene Therapeutics
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- InstitutionGreat Ormond Street Hospital for Children
Shares Allogeneic (off-the-shelf) cell therapy, CD19, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.